Skip to content

C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Status
Not yet recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523522-41-00
Enrollment
47
Registered
2026-04-07
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extensive-Stage Small Cell Lung Cancer

Brief summary

Phase 2: • Confirmed ORR as assessed by investigator based on RECIST v1.1 • AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention., Phase 3: • OS

Detailed description

Phase 2 • DOR as assessed by investigator based on RECIST v1.1 • PFS as assessed by investigator based on RECIST v1.1 • OS, Phase 2 • Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. • DLTs, Phase 2 • Predose and postdose concentrations of PF 08634404., Phase 2 • Incidence of ADA against PF-08634404., Phase 3 • PFS using RECIST v1.1 as assessed by BICR, Phase 3 • Confirmed ORR using RECIST v1.1 as assessed by BICR • Confirmed ORR using RECIST v1.1 as assessed by investigator, Phase 3 • PFS using RECIST v1.1 as assessed by investigator, Phase 3 • DOR using RECIST v1.1 as assessed by BICR • DOR using RECIST v1.1 as assessed by investigator, Phase 3 • AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s)., Phase 3 • Laboratory test abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0) and timing., Phase 3 • Predose and postdose concentrations of PF 08634404., Phase 3 • Incidence of ADA against PF 08634404., Phase 3 • Mean scores and change from baseline in the global health status/QoL, function, and symptom scores on the EORTC QLQ-C30 • Mean scores and change from baseline on the EORTC QLQ-LC13 • Time to definitive deterioration in the global health status/QoL, function, and symptom scores on the EORTC QLQ-C30 • Time to definitive deterioration in dyspnea, cough, or chest pain on the EORTC QLQ-LC13

Interventions

DRUGETOPOSIDE
DRUGATEZOLIZUMAB
DRUGCARBOPLATIN

Sponsors

Pfizer Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Phase 2: • Confirmed ORR as assessed by investigator based on RECIST v1.1 • AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention., Phase 3: • OS

Secondary

MeasureTime frame
Phase 2 • DOR as assessed by investigator based on RECIST v1.1 • PFS as assessed by investigator based on RECIST v1.1 • OS, Phase 2 • Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. • DLTs, Phase 2 • Predose and postdose concentrations of PF 08634404., Phase 2 • Incidence of ADA against PF-08634404., Phase 3 • PFS using RECIST v1.1 as assessed by BICR, Phase 3 • Confirmed ORR using RECIST v1.1 as assessed by BICR • Confirmed ORR using RECIST v1.1 as assessed by investigator, Phase 3 • PFS using RECIST v1.1 as assessed by investigator, Phase 3 • DOR using RECIST v1.1 as assessed by BICR • DOR using RECIST v1.1 as assessed by investigator, Phase 3 • AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s)., Phase 3 • Laboratory test abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 8, 2026